Tags

Type your tag names separated by a space and hit enter

[Miltefosine: a new remedy for leishmaniasis].
Ned Tijdschr Geneeskd. 2006 Dec 09; 150(49):2697-701.NT

Abstract

There is a need for a safe and effective oral treatment for cutaneous and visceral leishmaniasis. Miltefosine is the first oral drug that is efficacious against different forms ofleishmaniasis, however it is not equally effective against all Leishmania species. Miltefosine is an alkylphosphocholine, originally developed for the treatment of cancer. The mechanism of action is probably based on interference with the synthesis and degradation of parasitic membrane lipids. Little is known about the pharmacokinetics ofmiltefosine; an important characteristic is its long elimination half-life of seven days or longer. The most frequent adverse effects are of gastrointestinal origin. Miltefosine should not be used during pregnancy. Over thirty leishmaniasis patients have already been treated with miltefosine in the Netherlands.

Authors+Show Affiliations

Academisch Medisch Centrum/Universiteit van Amsterdam, afd. Inwendige Geneeskunde, onderafd. Infectieziekten, Tropische Geneeskunde en Aids, Meibergdreef 9, 1105 AZ Amsterdam. thomasdorlo@gmail.comNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article
Review

Language

dut

PubMed ID

17194005

Citation

Dorlo, T P C., et al. "[Miltefosine: a New Remedy for Leishmaniasis]." Nederlands Tijdschrift Voor Geneeskunde, vol. 150, no. 49, 2006, pp. 2697-701.
Dorlo TP, Eggelte TA, Beijnen JH, et al. [Miltefosine: a new remedy for leishmaniasis]. Ned Tijdschr Geneeskd. 2006;150(49):2697-701.
Dorlo, T. P., Eggelte, T. A., Beijnen, J. H., & de Vries, P. J. (2006). [Miltefosine: a new remedy for leishmaniasis]. Nederlands Tijdschrift Voor Geneeskunde, 150(49), 2697-701.
Dorlo TP, et al. [Miltefosine: a New Remedy for Leishmaniasis]. Ned Tijdschr Geneeskd. 2006 Dec 9;150(49):2697-701. PubMed PMID: 17194005.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Miltefosine: a new remedy for leishmaniasis]. AU - Dorlo,T P C, AU - Eggelte,T A, AU - Beijnen,J H, AU - de Vries,P J, PY - 2006/12/30/pubmed PY - 2007/1/26/medline PY - 2006/12/30/entrez SP - 2697 EP - 701 JF - Nederlands tijdschrift voor geneeskunde JO - Ned Tijdschr Geneeskd VL - 150 IS - 49 N2 - There is a need for a safe and effective oral treatment for cutaneous and visceral leishmaniasis. Miltefosine is the first oral drug that is efficacious against different forms ofleishmaniasis, however it is not equally effective against all Leishmania species. Miltefosine is an alkylphosphocholine, originally developed for the treatment of cancer. The mechanism of action is probably based on interference with the synthesis and degradation of parasitic membrane lipids. Little is known about the pharmacokinetics ofmiltefosine; an important characteristic is its long elimination half-life of seven days or longer. The most frequent adverse effects are of gastrointestinal origin. Miltefosine should not be used during pregnancy. Over thirty leishmaniasis patients have already been treated with miltefosine in the Netherlands. SN - 0028-2162 UR - https://www.unboundmedicine.com/medline/citation/17194005/[Miltefosine:_a_new_remedy_for_leishmaniasis]_ L2 - http://www.diseaseinfosearch.org/result/4166 DB - PRIME DP - Unbound Medicine ER -